PNR Ref
 PNR Req
 Blank PNRs
 Spotting
 Timeline
 Travel Tip
 Trip
 Race
 Social
 Greeting
 Poll
 Img
 PNR
 Pic
 Blog
 News
 Conf TL
 RF Club
 Convention
 Monitor
 Topic
 Bookmarks
 Rating
 Correct
 Wrong
 Stamp
 HJ
 Vote
 Pred
 @
 FM Alert
 FM Approval
 Pvt
News Super Search
 ↓ 
×
Member:
Posting Date From:
Posting Date To:
Category:
Zone:
Language:
IR Press Release:

Search
  Go  

पश्चिम रेलवे की शान, पश्चिम सुपरफास्ट एक्सप्रेस मेरी जान - Abdul Rehman

Full Site Search
  Full Site Search  
 
Fri Nov 27 00:10:12 IST
Home
Trains
ΣChains
Atlas
PNR
Forum
Topics
Gallery
News
FAQ
Trips/Spottings
Login
Advanced Search
<<prev entry    next entry>>
News Entry# 422487
Oct 23 (17:07) ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial (theprint.in)
*covid-19
0 Followers
221 views

News Entry# 422487  Blog Entry# 4756493   
  Past Edits
This is a new feature showing past edits to this News Post.
ICMR has submitted a proposal to the Modi govt recommending the cancer drug developed by AstraZeneca, which apparently improved clinical outcomes of patients with severe Covid-19.

New Delhi: The Indian Council of Medical Research (ICMR) has submitted a proposal before the Narendra Modi government’s panel of experts, calling for the dropping of “Interferon treatment” as part of the World Health Organization’s Solidarity trial.
...
more...

The Solidarity trial, an international clinical trial meant to help find an effective treatment for Covid-19, compares options against standard of care and assesses their relative effectiveness against the disease.

ICMR’s National AIDS Research Institute (NARI) — the institute responsible for conducting WHO’s trial in India — has presented its interim analysis to the government’s Subject Expert Committee (SEC). The SEC advises the country’s apex drug regulator, the Drug Controller General of India, on applications seeking approvals for new drugs, vaccines and clinical trials. 

Along with the analysis, NARI has submitted the “proposal for dropping of interferon arm and addition of Acalabrutinib arm in the study”.

Acalabrutinib is a cancer drug developed by British pharmaceutical giant AstraZeneca and is branded as Calquence.  

This is the second time NARI has proposed to include the Acalabrutinib for Covid treatment. Its addition was earlier discussed on 9 October when the committee had sought more “clarifications and justifications”. 

Now, the panel, which deliberated over the proposal on 20 October, has asked NARI to “present the latest version of protocol, before the committee for further deliberation,” according to the minutes of the meeting. 

Also read: India ran 122 medicine trials for Covid in first 4 months of pandemic, 67 of them were AYUSH

Results of Solidarity trial 

Solidarity is the largest multi-country trial that was started by WHO to estimate the impact of four repurposed drugs — Remdesivir, Hydroxychloroquine, Lopinavir and Interferon — on reducing deaths in hospitalised patients of Covid-19, compared to the existing standard of care. 

While the trial arms related to Hydroxychloroquine and Lopinavir were earlier discontinued when interim analyses showed no benefit, Interferon is likely to be replaced by Acalabrutinib. 

“These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalised Covid-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay,” researchers from the Solidarity trial reported in the pre-print paper on Medrxiv. “The mortality findings contain most of the randomised evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials.”

The cancer drug

Acalabrutinib was approved by the US Food and Drug Administration in 2019 for the treatment of certain types of cancers.

Acalabrutinib belongs to a class of medications called Bruton’s tyrosine kinase (BTK) inhibitor. These drugs block the action of the abnormal protein that signals cancer cells to multiply, stopping the growth of cancer cells.

In June, AstraZeneca had announced in the peer-reviewed journal Science Immunology that the drug “reduced markers of inflammation and improved clinical outcomes of patients with severe Covid-19”.

According to the company’s website, “The science supporting investigation of the use of Calquence in patients with severe Covid-19 is strong.”

Also read: Russia’s Sputnik vaccine to first be tested on 100 Indians before conducting a larger trial

 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises.

But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle.

ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here.

Support Our Journalism

RELATED ARTICLESMORE FROM AUTHOR

Remdesivir is first Covid drug to get US FDA approval

Here is why the ICMR study that found plasma therapy ineffective on Covid is being questioned

If you have Covid, this is what you and your doctor should watch out for

Most Popular

‘Look at India, it’s filthy, the air is filthy’ — Trump, once again, at presidential debate

Why IMF evaluators want India-style capital controls to be adopted around the world

Parliament joint committee summons Facebook, Twitter over data privacy issue
Scroll to Top
Scroll to Bottom
Go to Mobile site
Important Note: This website NEVER solicits for Money or Donations. Please beware of anyone requesting/demanding money on behalf of IRI. Thanks.
Disclaimer: This website has NO affiliation with the Government-run site of Indian Railways. This site does NOT claim 100% accuracy of fast-changing Rail Information. YOU are responsible for independently confirming the validity of information through other sources.
India Rail Info Privacy Policy